About: International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism
Creator	Hammond, A Drayton, ; Holzhausen, Jenna Horng, Michelle Peppard, Sarah Rech, Megan Sokol, Sarah Van Berkel, Megan
Source	PMC
abstract	OBJECTIVES: This survey sought to characterize the national prescribing patterns and barriers to the use of thrombolytic agents in the treatment of pulmonary embolism, with a specific focus on treatment during actual or imminent cardiac arrest. DESIGN: A 19-question international, cross-sectional survey on thrombolytic use in pulmonary embolism was developed, validated, and administered. A multivariable logistic regression was conducted to determine factors predictive of utilization of thrombolytics in the setting of cardiac arrest secondary to pulmonary embolism. SETTING: International survey study. SUBJECTS: Physicians, pharmacists, nurses, and other healthcare professionals who were members of the Society of Critical Care Medicine. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Thrombolytic users were compared with nonusers. Respondents (n = 272) predominately were physicians (62.1%) or pharmacists (30.5%) practicing in an academic medical center (54.8%) or community teaching setting (24.6%). Thrombolytic users (n = 177; 66.8%) were compared with nonusers (n = 88; 33.2%) Thrombolytic users were more likely to work in pulmonary/critical care (80.2% thrombolytic use vs 59.8%; p < 0.01) and emergency medicine (6.8% vs 3.5%; p < 0.01). Users were more likely to have an institutional guideline or policy in place pertaining to the use of thrombolytics in cardiac arrest (27.8% vs 13.6%; p < 0.01) or have a pulmonary embolism response team (38.6% vs 19.3%; p < 0.01). Lack of evidence supporting use and the risk of adverse outcomes were barriers to thrombolytic use. Working in a pulmonary/critical care environment (odds ratio, 2.36; 95% CI, 1.24–4.52) and comfort level (odds ratio, 2.77; 95% CI, 1.7–4.53) were predictive of thrombolytic use in the multivariable analysis. CONCLUSIONS: Most survey respondents used thrombolytics in the setting of cardiac arrest secondary to known or suspected pulmonary embolism. This survey study adds important data to the literature surrounding thrombolytics for pulmonary embolism as it describes thrombolytic user characteristic, barriers to use, and common prescribing practices internationally.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1097/cce.0000000000000132
has license	cc-by-nc-nd
sha1sum (hex)	442d7084183a388d9d9d6d0acf6c56d1468053ec
schema:url	https://doi.org/10.1097/cce.0000000000000132
resource representing a document's title	International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism
has PubMed Central identifier	PMC7314323
schema:publication	Crit Care Explor
resource representing a document's body	covid:442d7084183a388d9d9d6d0acf6c56d1468053ec#body_text
is schema:about of	named entity 'Treatment' named entity 'cardiac arrest' named entity 'International' named entity 'thrombolytic' named entity 'alteplase' named entity 'cardiac arrest' named entity 'ICU' named entity 'self-selection' named entity 'logistic regression' named entity 'nurses' named entity 'logistic regression' named entity 'survey study' named entity 'Society of Critical Care Medicine' named entity 'pharmacology' named entity 'alteplase' named entity 'cardiac arrest' named entity 'thrombolytic' named entity 'Anticoagulant' named entity 'cardiac arrest' named entity 'myocardial infarction' named entity 'Thrombolytic' named entity 'logistic regression' named entity 'thrombolytic' named entity 'adverse effects' named entity 'critical care' named entity 'Norway' named entity 'cardiac surgery' named entity 'thrombolytics' named entity 'cardiac arrest' named entity 'cardiac arrest' named entity '0.01' named entity '0.01' named entity 'thrombolytic' named entity 'thrombolytics' named entity 'thrombolytics' named entity 'thrombolytics' named entity 'cardiac arrest' named entity 'vascular medicine' named entity 'thrombolytic therapy' named entity 'thrombolytic' named entity 'pilot testing' named entity 'thrombolytics' named entity '0.01' named entity 'ROSC' named entity 'lysis' named entity 'emergency medicine' named entity 'cardiac arrest' named entity 'cardiac arrest' named entity 'cardiac arrest' named entity 'thrombolytic' named entity 'thrombolytics' named entity 'ROSC' named entity 'thrombolytic therapy' named entity 'cardiac arrest' named entity 'A192' named entity 'response bias' named entity 'Thrombolytic' named entity 'continuous infusion' named entity 'alteplase' named entity 'critical care' named entity 'United States' named entity 'ROSC' named entity 'teaching hospital' named entity '0.01' named entity 'cardiac arrest' named entity 'alteplase' named entity 'cardiac arrest' named entity 'thrombolytic' named entity 'return of spontaneous circulation' named entity 'ROSC' named entity 'ROSC' named entity 'thrombolytics' named entity 'ROSC' named entity 'ROSC' named entity 'Alteplase' named entity '95% CI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software